21 May 2009
Cytomegalovirus infection does not accelerate microvasculopathy development in heart transplant recipients
M Zakliczynski, A Krynicka-Mazurek, D Konecka-Mazurek, J Nożyński, S Żegleń, R Przybylski, M ZembalaAnn Transplant 2009; 14(1): 32-32 :: ID: 880313
Abstract
Background: It was confirmed in clinical studies with intravascular ultrasound
that even subclinical cytomegalovirus (CMV) infection may increase intimal
hyperplasia in transplanted heart's coronary arteries, which is observed at the end of the 1st year after the surgery. A potential influence of CMV on development of microvasculopathy is not known. Aim of the study was to compare occurrence of microvasculopathy in endomyocardial biopsies (EMBs) of heart transplant recipients with or without CMV infection.
Material/Methods: We performed a case-control retrospective study involving 58 pts. with CMV infection confirmed with the presence of pp65 antigen (49M/9F, 49±8y/o, ischemic c-pathy in 52%) and matched 58 control without CMV disease. Microvasculopathy was assessed using 4 degree grading system developed by Hiemann et al. in elective EMBs performed 1 month and 12 months after transplantation.
Results: Significant acute rejection was observed in 22 vs. 21% of 1st month's EMBs, and 3 vs. 5% of 12[sup]th[/sup] month's EMBs in CMV(+) and control group, respectively. Maximal microvasculopathy score was 2.05±0.93 vs. 1.88±0.94 in 1st month's EMBs, and 2.29±1.12 vs. 2.28±1.20 in 12[sup]th[/sup] month's EMBs, respectively. Progression of microvasculopathy score between 1st month and 12th month's EMBs was observed in 40 vs. 41% of pts, and regression occurred in 22 vs. 21% of pts, respectively. None of the differences was statistically significant.
Conclusions: Our data does not support the thesis that CMV infection promotes development of microvasculopathy in heart transplant recipients.
Keywords: CMV infections, Heart Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






